Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don’t respond to this immunotherapy for reasons not yet fully understood. Australian scientists have found a way to improve the effectiveness of cancer-fighting T cells within tumors, a potential step toward enabling more patients to respond to a life-saving immunotherapy.